Capricor Therapeutics (CAPR) Operating Income (2010 - 2026)

Capricor Therapeutics' Operating Income history runs 17 years deep, the most recent figure standing at -$36.8 million for Q1 2026.

• In Q1 2026, Operating Income fell 47.19% year-over-year to -$36.8 million; the TTM figure through Mar 2026 stood at -$119.9 million (down 109.38% YoY), while the FY2025 annual figure was -$108.1 million, down 154.07% from the prior year.
• Operating Income for Q1 2026 stood at -$36.8 million, down from -$29.2 million in the prior quarter.
• The five-year high for Operating Income was -$1.3 million in Q4 2023, with the low at -$36.8 million in Q1 2026.
• The 5-year median for Operating Income is -$8.2 million (2023), against an average of -$14.2 million.
• The sharpest annual moves came in 2023 and 2024: Operating Income surged 84.12% in 2023, then plunged 500.66% in 2024.
• Capricor Therapeutics' Operating Income stood at -$8.1 million in 2022, then soared by 84.12% to -$1.3 million in 2023, then slumped by 500.66% to -$7.7 million in 2024, then tumbled by 278.83% to -$29.2 million in 2025, then dropped by 26.12% to -$36.8 million in 2026.
• Business Quant data shows CAPR's Operating Income at -$36.8 million in Q1 2026, -$29.2 million in Q4 2025, and -$26.3 million in Q3 2025.